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Accepted 5 January 2011AbstractObjective: To investigate the effects of standardized soy extract on climacteric symptoms, lipid profiles, bone markers, and serum isoflavone
concentration in healthy Taiwanese postmenopausal women.
Materials and Methods: A multicenter, open-labeled, randomized, prospective, comparative study design was used. A total of 130 outpatients
who had undergone natural menopause were randomly administered either 70 mg or 35 mg soy extract daily for 24 weeks.
Results: The evidence suggests that the soy extract treatment that was administered to both groups for 1 month could help reduce climacteric
scores (reductions of 19.66% [p< 0.01] and 18.85% [p< 0.01] in the 35 mg and 70 mg groups compared with baseline, respectively), and the
efficacy was more potent after 6 months of treatment. Soy isoflavone significantly reduced the total cholesterol (reductions of 4.50% [p< 0.01]
and 3.06% [p< 0.05] in the 35 mg and 70 mg groups, respectively) and low density lipoprotein cholesterol levels (reductions of 4.67%
[p< 0.05] and 5.09% [p< 0.05] in the 35 mg and 70 mg groups, respectively) in patients with total cholesterol > 200 mg/dL after 6 months of
treatment. In patients with high bone turnover (urinary deoxypyridinoline/creatinine > 7.4 nM/mM), soy extract treatment reduced the deox-
ypyridinoline /creatinine level by 10.53% ( p< 0.05) and 11.58% ( p< 0.05) in the 35 mg and 70 mg groups, respectively. Serum levels of
isoflavone increased in both groups after 6 months of treatment.
Conclusion: Soy extract is highly efficacious at relieving menopausal symptoms and demonstrates a positive effect on the cardiovascular system
and skeleton.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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During menopause, the decline in ovarian hormones
(particularly estrogen) may result in unpleasant effects, such
as hot flushes and vaginal atrophy, that adversely affect quality
of life and may increase the risk of osteoporosis and coronary* Corresponding author. Department of Obstetrics and Gynecology, Taipei
Veterans General Hospital, 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan.
E-mail address: tsyang@vghtpe.gov.tw (T.-S. Yang).
1028-4559/$ - see front matter Copyright  2012, Taiwan Association of Obstetri
doi:10.1016/j.tjog.2012.04.011heart disease [1]. Hormone therapy (HT) is recognized as the
most effective treatment for the relief of the climacteric
symptoms of menopause [2,3]. Despite the clinical benefits
attributed to the use of HT in postmenopausal women,
compliance ranges from 10e50% due to the undesirable side
effects. Therefore, alternative therapies with the same benefits
of estrogen, but lower side effects, are needed for women who
refuse to use, are not compliant with, or have contraindications
for HT.
Phytoestrogens, or plant-based compounds with estrogenic
activity, received a great deal of attention after the publicationcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
230 T.-S. Yang et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 229e235of epidemiological data describing how they could be used as
a way to manage the symptoms of menopause and associated
diseases [4,5]. Isoflavones are the major type of phytoestrogen
that is of current interest, while the most important isoflavones
are genistein, daidzein, glycitein, and biochanin A. The
structures of these isoflavones resemble estrogen. Isoflavones
exhibit both estrogenic and antiestrogenic activities depending
on the concentrations of circulating endogenous estrogen,
estrogen receptors, and intracellular coregulators [6,7]. Iso-
flavones seem to have a higher binding affinity for estrogen
receptor-b (ERb) than ERa [8]. They are often referred to as
natural selective estrogen receptor modulators (SERMs) [5,9].
These different affinities could explain their antiestrogenic
effects on uterine and breast tissues [10] and their estrogenic
effects on bone [11] and blood vessels [12]. An inverse
association between soy intake and breast cancer risk has been
reported [13]. The normal Western adult’s self-reported intake
of soy isoflavones is around 5 mg/day and the serum iso-
flavone level ranges from 50e100 nM [14] compared with
> 50 mg/day intake and 3e5 mcM serum isoflavone plasma
concentration in the average Japanese adult [15].
Many randomized controlled clinical trials have been
conducted to evaluate the effects of soy isoflavones on vaso-
motor symptoms and cholesterol [16e22]. However, little
clinical data on the effects of isoflavones on bone mineral
density can be found in the literature [5]. Previously reported
contradictory results could be due to the large heterogeneity of
the soy derivatives that were studied. In this study, we used
a standardized purified isoflavone extract in capsule form that
is readily available as a dietary supplement. Its clinical
benefits had been previously reported [23,24]. Because the
background level of serum isoflavones is high in Taiwanese
adults (generally between the levels measured in Japanese and
Westerner patients because soy is a part of the habitual diet in
Taiwan; unpublished data), and because historically there is
a high drop-out rate from placebo control groups due to
ineffectiveness, we did not include a placebo control group in
this study. Instead, high-performance liquid chromatography
(HPLC) analysis of the plasma isoflavone concentration was
used to evaluate any changes after using the dietary supple-
ment. Therefore, in this multicenter, open-label, randomized,
prospective study, the objective was to evaluate the efficacy
and safety of isoflavones (35 mg or 70 mg daily) for allevi-
ating climacteric symptoms and their effects on lipid profiles
and bone markers in Taiwanese postmenopausal women.
Materials and methodsPatientsAgroup of 130 healthy postmenopausalwomen, eachwith an
intact uterus, was recruited from the gynecology out-patient
clinics of four medical centers in Taipei city. The inclusion
criteria required that all patients be women >45 years of age
with established menopause, which was diagnosed as amenor-
rhea for at least 3 months, a follicle stimulating hormone (FSH)
level > 40 mIU/L, and a plasma estradiol level< 25 pg/L.No patients had a history of liver disease, breast cancer, endo-
metrial cancer, thrombophlebitis, thromboembolic disorders
related to estrogen use, myocardial infarction, ischemic heart
disease, chronic renal disease, cerebrovascular accident,
uncontrolled hypertension, diabetes, metabolic bone disease, or
had received any hormone treatment within the previous 3
months. This study was approved by the Joint Institutional
Review Board (Taiwan) and informed written consent was
obtained from all of the patients enrolled in this study.TreatmentThis was a multicenter, open-label, randomized, compara-
tive, outpatient study. All patients participated in a 14-day
prestudy evaluation period followed by 6 months of treat-
ment. In all, 130 postmenopausal women were enrolled in this
study. A computer-generated randomized code stratification
system was used according to the medical center of enroll-
ment. One group (n ¼ 65) received 35 mg of soy extract
(Phyto Soya, a standardized isoflavone supplement prepared
from soy extract that contains 17.5 mg/cap soy isoflavones
consisting of 5.25 mg glycitin, 8.75 mg daidzein, and 3.5 mg
genistein; Arkopharma CARROS FRANCE) that was split
into two equal doses and orally consumed twice daily. Another
group (n ¼ 65) received 70 mg of soy extract that was also
split into two equal daily doses. The treatment period was 6
months, and the women received follow-up examinations after
the first, third, and sixth months.Laboratory methodsDuring the 6-month treatment period, the patients were
asked to participate in follow-up visits at baseline and 24
weeks after taking the soy extract. The follow-up examination
consisted of laboratory examinations, including hematology,
determination of blood chemistry and lipid profiles, hormonal
study, transvaginal sonography (TVS), and determination of
the isoflavone serum concentration. Urine and serum samples
were also collected for bone marker tests, and blood samples
were collected for laboratory tests. Lipid levels (total choles-
terol [TC], high-density lipoprotein cholesterol [HDL-C], low-
density lipoprotein cholesterol [LDL-C], and triglycerides
[TG]) were measured using an automatic analyzer (Hitachi-
7600; Nakashi, Japan).
To assess bone resorption, a second-void fasting urine
sample was taken in the early morning in order to determine
the concentration of deoxypyridinoline (Dpd) using
a commercial enzyme immunoassay (EIA) kit (Metra Bio-
system, Catalog No. 104827, Palo Alto, CA, USA). To assess
bone formation, a serum specimen was collected to measure
the bone-specific alkaline phosphatase (BAP) level using
a commercial EIA kit (Metra Biosystem).Serum isoflavone concentrationsSerum samples were deproteinated using 1% TCA. After
centrifugation, the clear supernatant was subjected to acid
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sate was neutralized and passed through a reverse-phase C18
column (Waters, Milford, MA.). Isoflavonoid compounds were
eluted using 2 mL methanol. The elution was dried under
a nitrogen flow. The dried material was redissolved in 100 mL
methanol and subjected to HPLC analysis that was carried out
on a GOLD system chromatograph (Beckman, Fullerton, CA,
USA). This system consists of a solvent delivery module
(model 126) and an ultraviolet detector (model 166). The
column configuration consisted of a Nova-Pak C18 (4 mm,
3.9 150 mm ID) reversed-phase column coupled to a Nova-
Pak C18 (4 mm, 3.9 20 mm ID) guard column (both from
Waters, Milford, MA). The gradient elution was carried out at
a flow rate at 0.8 mL/minute and a column temperature of
20C. The system consisted of acetonitrile and 10% acetic
acid in water (v/v). The gradient profile for separation was
optimized as 15/15/25/70/70/15% acetonitrile in 10% acetic
acid at 0/2/2.5/14.5/17.5/25 minutes, respectively. The
substances were detected and quantified at 260 nm.Clinical assessmentTable 1
Summary of patient demographics.
Characteristics 35 mg SSE
(n ¼ 65)
70 mg SSE
(n ¼ 65)
p
Age (y) 52.47  4.74 51.35  4.69 0.133
Height (cm) 156.14  5.26 157.16  4.79 0.146
Weight (kg) 55.33  7.28 55.51  8.02 0.838
BMI (kg/m2) 22.80  2.63 22.48  3.00 0.450
Years since menopause 3.90  3.76 3.35  4.12 0.550Each patient provided a complete medical history,
including past medical history, surgical procedures (especially
related to the reproductive and/or endocrine organs), and
obstetrical history. The baseline visit was scheduled for 14
days after the screening visit. Study visits were scheduled after
first, third, and sixth months of treatment. Menopausal
symptoms were recorded by the patients using a modified
Greene Climacteric Scale (GCS) and were scored at each
clinical visit. The GCS is a brief but comprehensive and valid
measure of climacteric symptomatology. Menopausal symp-
toms were categorized according to four main groups:
psychological, somatic, vasomotor, and urogenital atrophy.
Each group was evaluated as follows: 0 ¼ none, 1 ¼ a little,
2 ¼ quite a bit, and 3 ¼ extremely. The original criterion for
the urogenital atrophy scale is “loss of interest in sex”. The
modified GCS adds three more itemsdurinary tract
complaints/frequency, incontinence, and vaginal drynessdin
order to cover urogenital symptoms. Complete physical
examinations were performed at the baseline visit and after the
completion of 6 months of treatment. Analyses of any adverse
events (AEs) were performed after the first, third, and sixth
months of treatment. Diary cards were maintained by each
patient and used to record the frequency of hot flushes. Effi-
cacy was evaluated as a comparison of the changes in
frequency and severity of menopausal symptoms, lipid
profiles, and bone markers within each group (self-compar-
ison, baseline, and 6 months after beginning treatment), as
well as between the two treatment groups.E2 (pg/mL) 8.86  5.64 9.95  6.41 0.227
FSH (mIU/L) 74.65  17.28 77.27  17.50 0.313Statistical analysis
Systolic blood pressure (mmHg) 120.49  19.20 116.33  14.48 0.141
Diastolic blood pressure (mmHg) 76.35  11.50 73.94  9.49 0.176
Heart rate (beats/min) 74.26  9.67 73.16  8.59 0.429
BMI ¼ body mass index; SSE ¼ standardized soy extract. All values are the
means  SD.
p ¼ difference between the two groups.All measurements were listed and/or tabulated, and means
and standard deviations, if appropriate, were calculated.
Differences between baseline and 6 months after, as well as
differences between the two treatment groups, were comparedusing either the paired t test (within group), unpaired t test
(between groups), or ANOVA using the baseline as a covariate
for continuous variables, or using the Mantel-Haenszel method
for categorical data. All statistical tests were two-sided, and
a p value< 0.05 was considered statistically significant. HPLC
data were analyzed using independent and paired t tests and
with linear regression using a statistical software package
(SPSS 10.0 for Windows, Microsoft).
Results
Altogether, 130 patients were randomly assigned to the two
treatment groups (65 per treatment arm). These patients were
well balanced with respect to baseline characteristics. Table 1
lists the demographic and baseline features of the study
groups. No differences were statistically significant between
the two treatment groups. One hundred and seven patients (57
patients in the 35 mg and 50 patients in the 70 mg group)
completed the study. The drop-out rate was 17.7%. Most of the
discontinued patients were those who were lost on follow-up
(n ¼ 7) or those who experienced a lack of efficacy (n ¼ 12).Climacteric symptomsTable 2 shows the comparisons of the symptoms according
to the modified GCS between the two treatment groups.
Climacteric symptom scores (items 1e24) at baseline between
the two treatment groups were comparable (15.05  7.14 for
the 35 mg/day group and 15.60  9.45 for the 70 mg/day
group; p ¼ 0.73). As the results show, the scores were
significantly reduced in both treatment groups after 1 month of
treatment, and the efficacy was maintained throughout the 6
months of treatment. After the first month of treatment with
soy extract, the total climacteric symptoms score was reduced
by 3.84  5.73 points from baseline (decreased by
19.66  53.80% from baseline) in the 35 mg/day group and
reduced by 2.78  6.25 points from baseline (decreased by
18.85  45.66% from baseline) in the 70 mg/day group. There
was a statistically significant net change in the total climac-
teric symptoms scores within the groups after 1, 3, and 6
Table 2
Effect of treatment on menopausal symptoms (modified Greene Climacteric Scale).
Baseline 1 months 3 months 6 months
Treatment
35 mg SSE (n ¼ 57) 15.05  7.14 11.21  6.47 10.63  7.65 10.12  7.89
70 mg SSE (n ¼ 50) 15.60  9.45 12.82  9.89 11.74  9.46 11.00  8.90
Change from baseline
35 mg SSE (n ¼ 57) d 3.84  5.73 4.42  6.65 4.93  7.37
70 mg SSE (n ¼ 50) d 2.78  6.25 3.86  7.21 4.60  6.67
% change from baseline
35 mg SSE (n ¼ 57) d 19.66  53.80 21.80  59.00 30.17  48.91
70 mg SSE (n ¼ 50) d 18.85  45.66 25.63  52.28 28.86  42.97
SSE ¼ standardized soy extract.
All values are the means  SD. All values are significantly different from baseline (p< 0.01).
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difference was observed between the two treatment groups.
Table 3 shows the comparisons of the individual symptoms
according to the modified GCS between the two treatment
groups. No statistically significant difference was observed
between groups (p ¼ 0.506).Lipid profilesNo statistically significant differences were observed in any
item at baseline between the two treatment groups. After 6
months of treatment, none of the lipid profiles were signifi-
cantly different from baseline within each group. As shown in
Table 4, in the subgroup analysis of patients with TC
>200 mg/dL (n ¼ 69), TC was reduced by 11.30  23.73 mg/
dL (decreased by 4.50  10.29% from baseline) in the 35 mg/
day group and by 7.90  18.60 mg/dL (decreased by
3.06  7.61% from baseline) in the 70 mg/day group after 6
months of treatment; however, no statistically significant
difference was found between the two treatment groups
( p ¼ 0.79). HDL was reduced by 2.63  9.19 mg/dL
(decreased by 2.56  11.07% from baseline) in the 35 mg/day
group and increased by 0.34  7.87 mg/dL (increased by
1.79  12.03% from baseline) in the 70 mg/day group, but this
difference was not significant ( p ¼ 0.08 and 0.82, respec-
tively). LDL showed statistically significant changes within
each treatment group after 6 months of treatment: LDL was
reduced by 8.45  22.97 mg/dL (decreased by 4.67  14.64%
from baseline) in the 35 mg/day group and by
8.97  22.49 mg/dL (decreased by 5.09  13.30% fromTable 3
Observed data on the individual symptoms in terms of the modified Greene Clima
35 mg SSE (n ¼ 57)
Baseline 6 months Change (%) p
P (1e11) 6.67  3.62 4.09  4.05 40.65  49.68 <
S (12e18) 4.83  3.06 3.02  2.66 21.32  95.65 <
V (19e20) 1.65  1.55 0.74  1.01 43.60  75.84 <
UG (21e24) 3.21  2.31 2.26  2.22 13.91  88.19 <
P ¼ psychological scale; S ¼ somatic scale; V ¼ vasomotor scale; UG ¼ urogen
p ¼ difference from baseline (within the group).
# No statistically significant difference was observed between the two treatmentbaseline) in the 70 mg/day group. There was no statistically
significant difference between the two treatment groups
( p ¼ 0.93).
In the subgroup analysis of patients with TG >103 mg/dL
(n ¼ 39), there was no statistically significant difference in TG
between the two groups at baseline ( p ¼ 0.99). TG was
significantly reduced by 22.45  38.03 mg/dL (decreased by
14.20  25.75% from baseline) in the 35-mg/day group and by
28.00  50.97 mg/dL (decreased by 17.23  30.46% from
baseline) in the 70 mg/day group after 6 months of treatment.
No statistically significant difference was found between the
two treatment groups ( p ¼ 0.70).Bone markersTable 5 shows the relative changes from baseline of the
bone resorption and formation marker (urinary Dpd/creatinine
[Cr] and serum BAP) levels after short periods of soy extract
treatment. The baseline levels of Dpd/Cr and BAP were
comparable between the two treatment groups ( p ¼ 0.42 and
0.79, respectively). At 6 months, there was no statistically
significant difference within or between groups. In the
subgroup analysis of the patients with Dpd/Cr > 7.4 nM/mM
(n ¼ 44), a reduction in bone resorption activity was shown.
The cut-off point of Dpd/Cr for choosing a subgroup followed
the reference range that was provided with the commercial
assay kit (as described in the Materials and Methods section)
and was validated in our laboratory. The baseline level of Dpd/
Cr between the two subgroups was comparable
(8.93  1.22 nM/mM for the 35 mg/day group andcteric Scale.
70 mg SSE mg# (n ¼ 50)
Baseline 6 months Change (%) p
0.01 7.42  5.61 5.18  4.89 30.52  61.67 <0.01
0.01 4.78  3.03 3.02  2.57 22.30  79.00 <0.01
0.01 1.78  1.67 0.82  1.04 39.00  71.22 <0.01
0.01 2.60  2.02 1.82  1.60 25.71  42.70 <0.01
ital scale; SSE ¼ standardized soy extract. All values are the means  SD.
groups (p ¼ 0.506).
Table 4
Lipid profile of postmenopausal women during the 6 months of treatment with soy extract.
Lipids Baseline (mg/dL) 6 mo (mg/dL) Change (%) p Baseline (mg/dL) 6 mo (mg/dL) Change (%) p
35 mg SSE (n ¼ 57) 70 mg SSE (n ¼ 50)
TC 215.40  33.42 209.19  30.00 2.03  11.88 0.06 207.30  32.77 205.08  28.80 0.32  10.43 0.46
HDL-C 64.81  14.86 62.89  13.65 1.38  16.81 0.14 63.70  14.82 64.14  13.76 1.81  12.08 0.71
LDL-C 139.65  31.58 135.37  28.79 1.41  16.44 0.16 132.14  30.11 129.44  26.27 0.15  16.35 0.39
TG 101.21  43.81 99.89  44.25 4.63  45.16 0.81 92.10  50.68 85.80  43.24 1.02  36.19 0.24
TC subgroup (n ¼ 69)
35 mg SSE (n ¼ 40) 70 mg SSE (n ¼ 29)
TC 232.33  23.33 221.03  25.48 4.50  10.29 0.00 227.38  25.25 219.48  21.12 3.06  7.61 0.03
HDL-C 67.98  14.27 65.35  12.99 2.56  11.07 0.08 64.00  13.79 64.34  11.86 1.79  12.03 0.82
LDL-C 153.53  25.88 145.08  26.82 4.67  14.64 0.03 150.86  23.11 141.90  23.02 5.09  13.30 0.04
TG 100.98  40.13 99.15  40.00 5.55  49.88 0.78 97.72  47.51 89.76  35.07 0.38  34.47 0.19
TG subgroup (n ¼ 39)
35 mg SSE (n ¼ 22) 70 mg SSE (n ¼ 17)
TC 221.00  31.64 209.77  33.68 4.66  11.45 0.05 211.82  38.28 206.47  35.85 3.06  7.31 0.25
HDL-C 56.64  13.55 57.55  15.10 2.28  16.26 0.62 53.53  12.71 55.47  12.59 1.79  12.03 0.14
LDL-C 149.00  31.84 139.73  32.73 4.97  17.44 0.11 138.06  33.01 133.00  32.93 5.09  13.30 0.32
TG 146.23  34.07 123.77  39.41 14.20  25.75 0.01 146.47  49.03 118.47  52.09 17.23  30.46 0.04
TC subgroup: total cholesterol > 200 mg/dL; TG subgroup: triglyceride > 103 mg/dL; SSE ¼ standardized soy extract. All values are the means  SD.
p< 0.05: significantly different from baseline (within the group).
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After 6 months, a decrease of 10.53  22.58% from baseline
was observed in the Dpd bone resorption marker level in the
35 mg/day group and a decrease of 11.58  19.55% was noted
in the 70 mg/day group. However, no statistically significant
difference between the two treatment groups was seen
( p ¼ 0.82).
In the subgroup analysis of the patients with a BAP level >
18 U/L, the baseline BAP levels of the two groups were
comparable (24.71  4.60 U/L in the 35 mg/day group and
27.02  9.00 U/L in the 70 mg/day group; p ¼ 0.15). The cut-
off point of BAP for choosing a subgroup followed the
reference range provided with the commercial assay kit (as
described in Materials and Methods section) and was validated
in our laboratory. No statistically significant difference in the
net change in BAP (from baseline) between ( p ¼ 0.18) or
within the two treatment groups ( p ¼ 0.81 for the 35 mgTable 5
Bone turnover markers in postmenopausal women during short-term treatment wit
Baseline
Dpd/Cr (nM/mM) 35 mg SSE 7.32  1.9
70 mg SSE 7.22  1.7
BAP (U/L) 35 mg SSE 22.10  6.1
70 mg SSE 23.33  9.4
Subgroup Dpd/Cr (nM/mM) > 7.4 (n ¼ 44)
Dpd/Cr (nM/mM) 35 mg SSE (n ¼ 27) 8.93  1.2
70 mg SSE (n ¼ 17) 9.06  1.1
BAP (U/L) 35 mg SSE (n ¼ 27) 22.88  5.5
70 mg SSE (n ¼ 17) 25.80  7.77
Subgroup BAP (U/L) >18 (n ¼ 76)
Dpd/Cr (nM/mM) 35 mg SSE (n ¼ 42) 7.44  2.08
70 mg SSE (n ¼ 34) 7.64  1.7
BAP (U/L) 35 mg SSE (n ¼ 42) 24.71  4.6
70 mg SSE (n ¼ 34) 27.02  9.0
Dpd ¼ deoxypyridinoline; Cr ¼ creatinine; BAP ¼ bone-specific alkaline phosphgroup; p ¼ 0.87 for the 70 mg group) was seen during the
treatment period.HPLC dataThe baseline levels of daidzein and genistein were compa-
rable between the two treatment groups ( p ¼ 0.41 and 0.69,
respectively). The genistein serum level was higher than the
daidzein level due to the subjects’ dietary soy composition
(unpublished data). Table 6 shows that the mean serum levels of
daidzein in both the 35 and 70 mg soy extract treatment groups
increased significantly (3.7- and 4.4-fold, respectively;
p< 0.01) after 6 months after treatment. Serum levels of gen-
istein increased by 1.2-fold in the low-dosage group and 1.1-fold
in the high-dosage group ( p ¼ 0.03; 0.04), respectively. There
was no statistically significant difference between the two
treatment groups after the treatment period (all p> 0.1).h soy extract.
6 months Change (%) p
1 7.44  2.05 7.08  39.16 0.70
0 7.17  1.62 2.38  24.41 0.84
3 22.93  7.10 6.33  30.33 0.27
2 23.91  8.81 5.90  23.46 0.48
2 7.97  2.20 10.53  22.58 0.02
8 7.96  1.74 11.58  19.55 0.02
9 22.86  5.27 1.24  15.38 0.98
24.88  8.12 2.02  18.58 0.52
7.39  2.11 0.24  18.28 0.88
4 7.30  1.52 1.68  21.74 0.24
0 24.55  6.07 0.24  18.28 0.81
0 26.85  8.89 0.71  19.46 0.87
atase; SSE ¼ standardized soy extract. All values are the means  SD.
Table 6
Serum isoflavone (mean  SD ng/mL) levels at baseline and after 24 weeks of
soy extract treatment.
35 mg SSE (n ¼ 57) 70 mg SSE (n ¼ 50)
Baseline 6 months Baseline 6 months
Daidzein 126  23 473  46* 100  20 444  57*
Genistein 287  23 351  32* 316  31 415  45*
SSE ¼ standardized soy extract; SD ¼ standard deviation.
*Significantly different from baseline: p< 0.05.
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line in terms of body weight, blood pressure, pulse rate,
endometrial thickness, or laboratory data within or between
the two treatment groups. In terms of the frequencies of
spotting and bleeding analysis, most patients did not demon-
strate spotting or bleeding during each cycle during treatment.
No significant changes were noted in the vaginal epithelium or
endothelium using transvaginal sonography (TVS).SafetyFifteen incidences of AEs (7 in the 35 mg/day group and 8
in the 70 mg/day group) were reported. Five and six patients
reported soy extract-related AEs in the 35 and 70-mg/day
groups, respectively ( p ¼ 0.811). The soy extract-related AEs
were mostly mild. The most frequently reported soy extract-
related AE was nausea (3 in the 35 mg group and 3 in the
70 mg group), followed by breast tenderness (1 in the 35 mg
group and 3 in the 70 mg group). All of the AEs were stan-
dardized using the CORSTART coding system.
Discussion
Previous data on the clinical efficacy of isoflavone are
conflicting and difficult to analyze because of variations in the
examined populations, duration of exposure to dietary iso-
flavone, study designs, and responsiveness in postmenopausal
women to isoflavone supplementation. Furthermore, these
discrepancies may be related to the specific sources of the
isoflavones and individual metabolisms. Washburn et al [25]
suggested that having a consistent circulating level of iso-
flavone may be more efficacious than a higher single dose.
We did not have a placebo control group in this study
because the background level of plasma isoflavones in
Taiwanese adults is high (unpublished data), and experientially
there is a high drop-out rate from placebo control groups due
to ineffectiveness. In addition, the limitations of the small
number of patients and the short duration of follow-up in this
study should be recognized. Therefore, we used HPLC to
analyze the plasma isoflavone concentration in order to eval-
uate changes following dietary supplementation.
This study presents, for the first time, the serum levels of
isoflavones in Taiwanese postmenopausal women. After
administering a twice-daily standardized soy extract dietary
supplement for 6 months, a substantial increase in the serumisoflavone level was achieved. Furthermore, the increased
isoflavone level reflects the measurement of daidzein and
genistein in the intervention material (i.e., soy extract).
However, no dose-dependent response in terms of daidzein or
genistein serum levels was observed in the 35 or 70 mg
groups. This may be due to the high background level of
serum isoflavone in Taiwanese women, as well as the constant
clearance of isoflavones. Variations in absorption also played
an important role. Further kinetic studies may explain these
conflicting results.
This study confirms that soy extract, when administered at
a daily dose of 35 or 70 mg, effectively and safely relieves
climacteric-related symptoms in postmenopausal women.
These results are in line with those of Albert et al [23] and
Evelyne et al [24]. The significant reduction in climacteric
symptomswith the use of soy extractwas superior to the placebo
effect. However, there was no statistically significant difference
between the 35 and 70 mg groups (p¼ 0.506), which was partly
due to similar plasma concentrations. Jou et al [26] suggested
that a dose 70 mg/day is needed to provide earlier onset in the
improvement of somatic symptoms.
Based on previously reported positive findings, a health
claim for the role of soy supplements in reducing serum
cholesterol was granted by the United States Food and Drug
Administration. The American Heart Association also recom-
mends the consumption of soy protein and isoflavones in order
to reduce the risk of coronary heart disease (CHD). Researchers
believe that isoflavones are responsible for most of the hypo-
cholesterolemic effects of soy supplements [27,28]. The
potential mechanisms include: (1) direct phytoestrogenic
effects; (2) increased arterial compliance; and (3) direct anti-
oxidant properties. Although the lipid-lowering effects of iso-
flavones aremodest andmay not achieve target lipid parameters,
it is possible that isoflavones may contribute to a lower risk of
CHD if consumed over many years in conjunction with other
lipid-lowering strategies [28]. An improvement in blood lipid
levels has been noted to be related to the initial degree of
hyperlipidemia in each patient [27,29,30]. However, due to our
small sample size and the length of treatment, some true
correlations might not have been observed. Herein, a statisti-
cally significant reduction of TG, as well as TC and LDL, was
demonstrated in hypertriglycemic and hypocholesterolemic
patients. This is contradictory to the usual results of oral
estrogen intake, in which isoflavones cause a decrease in TG.
Further studies are warranted on the use of isoflavones in
combination with other lipid-lowering medicines for the
management of hyperlipidemia. The National Institutes of
Health’s National Center for Complementary and Alternative
Medicine is currently supporting Professor Howard N. Hodis of
the University of Southern California, who is conducting the
Women’s IsoflavoneSoyHealth (WISH) trial. This ongoing trial
will last 2.5 years and will help to determine if isoflavone-
containing soy protein treatments reduce the progression of
atherosclerosis in postmenopausal women. Changes in the
intimal media thickness of the carotid artery will be the primary
endpoint. We should await the arrival of more data before
rushing to judgment about the effects of isoflavone.
235T.-S. Yang et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 229e235Kritz-Silverstein et al [31] indicated that the bone-sparing
effects of short-term supplemental isoflavones would be
more apparent in high bone-turnover patients. Most of the
patients included in this study were in the normal range of
bone turnover. Although a statistically significant reduction in
Dpd/Cr was seen in the high-resorption subgroup, there is
a need for further studies on the long-term effects on bone
activity, including the study of high-dose isoflavones in rapid
bone-losing menopausal women.
Conclusion
This study assessed the effects of standardized isoflavone
supplement soy extract on climacteric symptoms, lipid
profiles, and bone markers in postmenopausal women in
Taiwan. Based on the results obtained in this preliminary
study, soy extract demonstrates a good efficacy for relieving
menopausal symptoms, in addition to good tolerance and
compliance. The data also suggest the positive effects of soy
extract on the cardiovascular system and skeleton. It could,
therefore, be used by women who suffer from menopausal
symptoms and who choose not to take HT for personal or
medical reasons.
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